All In Biotech

Drug Trial Radar · NCT05138133

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

A Multicentre Randomized Double-Blind Placebo Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 363 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

363

Actual

Start

Feb 15, 2022

Primary completion

Feb 23, 2027

Study completion Oct 4, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis

Conditions

  • Lupus Nephritis

Interventions

  • AnifrolumabDrug

    Anifrolumab intravenous infusion (IV)

  • PlaceboDrug

    Placebo intravenous infusion (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in proportion of participants with CRR (Complete Renal Response) in anifrolumab group compared with placebo groupTime frame: Week 52

Locations

164 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Glendale, Arizona

  • Research Site

    La Palma, California

  • Research Site

    Los Angeles, California

  • Research Site

    Upland, California

  • Research Site

    Plantation, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Louisville, Kentucky

  • Research Site

    Summit, New Jersey

  • Research Site

    Manhasset, New York

  • Research Site

    New York, New York

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Middleburg Heights, Ohio

  • Research Site

    Colleyville, Texas

  • Research Site

    Edinburg, Texas

  • Research Site

    El Paso, Texas

  • Research Site

    Houston, Texas

  • Research Site

    CABA, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    La Plata, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    San Juan, Argentina

  • Research Site

    Brussels, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Campinas, Brazil

  • Research Site

    Cuiabá, Brazil

  • Research Site

    Maringá, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Recife, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    São José do Rio Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Bengbu, China

Showing 40 of 164 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.